A modified rapid monoclonal antibody‐specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation

Campbell, Kate; Rishi, K.; Howkins, G.J.; Gilby, D.; Mushens, Rosey; Ghevaert, Cédric; Metcalfe, Paul; Ouwehand, Willem H.; Lucas, Geoff

doi:10.1111/j.1423-0410.2007.00989.x

Cited by 56 publications

(48 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, HP-2b3a cells have expressed stably the GPIIb and GPIIIa complex for more than 2 years (data not shown). Campbell et al [34] pointed out a potential risk of falsepositive cases in the MAIPA assay resulting from the co-immunoprecipitation of GPIIb/IIIa with HLA class I molecules. Since the HP cell line panel established in the present study was derived from the K562 cell line that does not react with HLA class I antibodies, the MAIPA assay using these cells would exclude this risk of false-positive results.…”

Section: Discussionmentioning

confidence: 99%

“…The MAIPA assay was performed according to the method described by Crossley [23] and Campbell [34] with minor modifications using 1.0 9 10 6 panel cells substituting for platelets. We used HP-mock cells and HP-2b3a cells as control cells.…”

Section: Maipa Assaymentioning

confidence: 99%

“…4Reactivity of serum samples to the HP cell line panel. Reactivity of HLA class I, HPA-1a, and HPA-4b antibodies to HP-mock, HP-2b3a, and HP-4b cells were determined using the MAIPA assay by the method described by Crossley[23] and Campbell[34] with minor modification. Their optical densities (at 450 nm) are expressed as bound IgG.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Establishment of a cell line panel for the detection of antibodies against human platelet antigen 4b

Hayashi

Amakishi²,

Inoue

et al. 2011

Int J Hematol

View full text Add to dashboard Cite

Antibodies against human platelet antigens (HPAs) play important roles in thrombocytopenia. In Japan, HPA-4b antibody is frequently responsible for HPA-related neonatal alloimmune thrombocytopenia. A highly sensitive assay using platelets has been developed for the detection of antibodies against HPAs. However, it is difficult to obtain the platelets expressing specific HPAs required for the assay. Therefore, an alternative method not requiring platelets would be helpful to detect antibodies against HPAs. Glycoprotein IIIa (GPIIIa) cDNA encoding HPA-4b was individually co-transduced with that of wild-type GPIIb in K562 cells, which is a non-adherent cell line, using a retroviral vector. The expression of transgene products in cultured cells were observed for over 6 months. Next, to evaluating the sensitivity and specificity of this cell line panel, we performed monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay with a serum previously identified by another method. All HPA-4b antibodies in serum samples were positive, and all serum samples, including normal serum and serum containing HLA antibodies were negative. No difference was observed in the specificity and sensitivity between our method and conventional MAIPA using platelets. The present results indicate that this established cell line panel permits highly sensitive detection of specific antibodies against HPA-4b.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Maipa Assaymentioning

confidence: 99%

See 1 more Smart Citation

Establishment of a cell line panel for the detection of antibodies against human platelet antigen 4b

Hayashi

Amakishi²,

Inoue

et al. 2011

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…The odyssey towards HPA-1a alloantibody detection based on immobilization of platelet antigens with monoclonal antibodies (MoAbs) in the assay known as monoclonal antibody-specific immobilization of platelet antigens assay (MAIPA) was first described by Kiefel et al (1987). Since then, dramatic efforts and progress have been made towards establishing alternative assays for HPA-1a alloantibody detection (Stafford et al, 2008;von dem Borne et al, 1978;Campbell et al, 2007;Meyer et al, 2006a,b;Bakchoul et al, 2007;Fujiwara et al, 2009;Wautier, 2000;Thibaut et al, 2012;Chong et al, 2011;Quiel et al, 2012). However, such assays are hampered by the limited availability of MoAbs and suitable platelet donors.…”

Section: Introductionmentioning

confidence: 96%

Development of a single-antigen magnetic bead assay (SAMBA) for the sensitive detection of HPA-1a alloantibodies using tag-engineered recombinant soluble β3 integrin

Skaik¹,

Battermann²,

Hiller³

et al. 2013

Journal of Immunological Methods

View full text Add to dashboard Cite

“…Direct tests (for platelet bound IgG and IgM) were determined using the platelet immunofluorescence test (PIFT) 11 and by the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay 12 to determine whether there was platelet bound IgG localized to platelet glycoproteins (GP)IIb/IIIa, GPIa/IIa or GPIb/IX. A patient was considered to have platelet autoantibodies if the results of the direct PIFT or the direct MAIPA assay were greater than the mean +3 standard deviations of the values obtained for platelets obtained from at least 3 normal blood donors on the same day.…”

Section: Anti-platelet Autoantibodiesmentioning

confidence: 99%

A distinct plasmablast and naive B-cell phenotype in primary immune thrombocytopenia

et al. 2016

Self Cite

View full text Add to dashboard Cite

P rimary immune thrombocytopenia is an autoimmune disorder in which platelet destruction is a consequence of both B-and T-cell dysregulation. Flow cytometry was used to further characterize the B-and T-cell compartments in a cross-sectional cohort of 26 immune thrombocytopenia patients including antiplatelet antibody positive (n=14) and negative (n=12) patients exposed to a range of therapies, and a cohort of matched healthy volunteers. Markers for B-cell activating factor and its receptors, relevant B-cell activation markers (CD95 and CD21) and markers for CD4 + T-cell subsets, including circulating T-follicular helper-like cells, were included. Our results indicate that an expanded population of CD95 + naïve B cells correlated with disease activity in immune thrombocytopenia patients regardless of treatment status. A population of CD21-naïve B cells was specifically expanded in autoantibody-positive immune thrombocytopenia patients. Furthermore, the B-cell maturation antigen, a receptor for B-cell activating factor, was consistently and strongly up-regulated on plasmablasts from immune thrombocytopenia patients. These observations have parallels in other autoantibody-mediated diseases and suggest that loss of peripheral tolerance in naïve B cells may be an important component of immune thrombocytopenia pathogenesis. Moreover, the B-cell maturation antigen represents a potential target for plasma cell directed therapies in immune thrombocytopenia.

show abstract

A modified rapid monoclonal antibody‐specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation

Abstract: The MR-MAIPA assay offers improved turnaround for the detection of HPA antibodies without loss of sensitivity.

Cited by 56 publications

References 32 publications

Establishment of a cell line panel for the detection of antibodies against human platelet antigen 4b

Establishment of a cell line panel for the detection of antibodies against human platelet antigen 4b

Development of a single-antigen magnetic bead assay (SAMBA) for the sensitive detection of HPA-1a alloantibodies using tag-engineered recombinant soluble β3 integrin

A distinct plasmablast and naive B-cell phenotype in primary immune thrombocytopenia

Contact Info

Product

Resources

About